Phythera Therapeutics, Inc

Phythera Therapeutics, Inc. was started to test, develop and improve promising metastatic cancer herbal medications. Many small bioactive phyto-molecules used in biomedicine have been derived from plants (hence –Phythera Therapeutics). The cocktail of drugs is expected to be better than one molecule for managing complex diseases with no available treatments. We see the potential of these medicines carrying a cocktail of many small bioactive molecules to substantially improve the treatment of cancer, either as an auxiliary or even as the main treatment method. Optimizing and improving these small molecules to maximize their efficacy to combat metastatic cancers, and converting them into potent and robust novel bioactive compounds is Phythera's main overarching goal. We leverage our expertise in 3D cell biology and transcriptomics to test the small molecule compounds to define and improve their efficacy in 3D tissue model systems, either as a single compound or as a combination of several most potent small molecule drugs. The 3D biology (organoids) provides a wealth of information about in vivo biology, which the 2D conventional approaches may not provide, and are the most relevant models for testing novel drugs. The team's proven deep expertise in stem cell biology enables us to study the impact of our candidate molecules on the most elusive and most malignant cancer stem cells and develop drug combinations, optimized for a specific disease. Last but not least, our team has a strong interest in regenerative medicine approaches for inducing tissue regeneration and improving tissue homeostasis, the key to wellness and enduring health. Small molecule compounds derived from plants possess many of the properties promoting tissue regeneration and modulating homeostasis in tissue. Enhancing these properties and converting them into new treatments is Phythera's 2nd overarching goal.